Hemostatic Patch/Collagen Sealant and Polyethylene Glycol (Hemopatch) in the Postoperative of the Thyroidectomy.

Goiter Clinical Trial

Official title:

Regular Treatment Versus Hemostatic Patch/Collagen Sealant and Polyethylene Glycol (Hemopatch) in the Immediate Postoperative of the Thyroidectomy, Unicentric Study, Non-inferiority, Open and Randomized (Tiropatch Study)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05103956
• Other study ID #: TIROPATCH
• Status: Recruiting
• Start date: October 1, 2021
• Est. completion date: April 1, 2022

Study information

• Verified date: October 2021
• Source: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
• Contact: Juan Manuel Martos Martínez
• Phone: 955 01 20 00
• Email: jmmartos66[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Observational study with non-inferiority, prospective, randomized (1: 1) and open-label medical device. The study has 2 treatment groups (HEMOPATCH® versus standard hemostasis).

Description:

The main objective is to determine if there is a reduction in the volume of exudate in the surgical bed with the application of the collagen and polyethylene glycol hemostatic agent. The present study includes patients undergoing total thyroidectomy for multinodular goiter in the Endocrine Surgery Unit of the Virgen del Rocío University Hospital. The estimated sample calculation of patients enrolled in the study is 108 (2 groups, 1:1 ratio). The patients don´t know what type of hemostatic the patients are going to receive (single blind). The duration of patient follow-up will be 30 +/- 10 days after surgery.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 108
• Est. completion date: April 1, 2022
• Est. primary completion date: April 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients of legal age.
• Indication of total thyroidectomy due to multinodular goiter.
• Accept to enter the study and sign the informed consent.
• Patient willing and able to complete clinical trial procedures, as described described in the protocol.

Exclusion Criteria:

• Patients under 18 years of age.
• Patients with surgical indication for hemithyroidectomy or subtotal thyroidectomy (eg unilateral nodular goiters).
• Multinodular goiter with high suspicion or preoperative diagnosis of cancer (Bethesda V and VI and / or infiltration of neighboring structures on imaging tests).
• Known allergy or hypersensitivity to a component of the Hemopatch® investigational treatments, riboflavin, or bovine proteins.
• Concurrent or prior therapy with systemic pharmacological agents that promote blood clotting, including, but not limited to, tranexamic acid, activated factor VII, fibrinogen, and aprotinin.
• Pregnancy or breastfeeding.
• Refuse to enter the study and sign the informed consent.
• Not agreeing to carry out all the planned follow-up.
• Concurrent participation in another clinical trial with a medical device or drug or with interfering endpoints Inability to understand the nature and scope of the trial and the required procedures.

Criteria to be verified during surgery (Intraoperative exclusion criteria):

• Persistent major bleeding after primary hemostasis.
• Infection of the surgical area.

Related Conditions & MeSH terms

• Goiter

Locations

Country	Name	City	State
Spain	Hospital Universitario Virgen del Rocío	Sevilla

Sponsors (1)

Lead Sponsor	Collaborator
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of changes in the exudate volume of the surgical bed with the application of the hemostatic agent of collagen and polyethylene glycol.	Fixed periods of time will be established to evaluate the exudate from the surgical bed.; It will be evaluated 18 hours after surgery by cervical ultrasound.	Up to 18 hours.
Secondary	Rate of changes in the patient's symptoms in the postoperative period of thyroidectomy after the application of the hemostatic agent of collagen and polyethylene glycol.	Decrease in the number of dyspnea at 24 hours and 30 days postoperatively.	Up to 4 weeks.
Secondary	Improvement in patient satisfaction after the application of the collagen and polyethylene glycol hemostatic agent, in relation to the surgical experience in the postoperative period of thyroidectomy.	Satisfaction survey at discharge and 30 days after the intervention.	Up to 4 weeks.
Secondary	Rate of improvement in postoperative complications of thyroidectomy after the application of the collagen and polyethylene glycol hemostatic agent.	Performance of the Trousseau test every 8 hours from surgery to hospital discharge and Calcemia (mg/dl) at discharge and at check-up in consultations (30 days) with total proteins.	Up to 4 weeks.
Secondary	Incidence rate of adverse effects after the use of the collagen and polyethylene glycol hemostatic agent in thyroid surgery.	Number of adverse events that have occurred in study patients.	Up to 24 weeks.